The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective

Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada®) is a highly effica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Neurol Disord
Autors principals: Alroughani, Raed, Van Wijmeersch, Bart, Al Khaboori, Jabber, Alsharoqi, Isa Ahmed, Ahmed, Samar F., Hassan, Ali, Inshasi, Jihad, Krieger, Derk W., Shakra, Mustafa, Shatila, Ahmed Osman, Szolics, Miklos, Khallaf, Mohamed, Ezzat, Aly
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7498833/
https://ncbi.nlm.nih.gov/pubmed/32973927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420954119
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars